Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma-Reference-Cited by-同舟云学术

Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma

Published:2016-05-23 Issue:31 Volume:7 Page:50624-50634
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Fan Yun¹²,Jiang Youhua³,Zhou Xinming³,Chen Qixun³,Huang Zhiyu¹,Xu Yanjun¹,Gong Lei¹,Yu Haifeng¹,Yang Haiyan¹,Liu Jinshi³,Lei Tao¹,Zhao Qiang³,Mao Weimin¹²

Affiliation:

1. Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, China

2. Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology and Cancer Research Institute, Hangzhou, China

3. Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. XRCC2 knockdown effectively sensitizes esophageal cancer to albumin-paclitaxel in vitro and in vivo;Biochemical Genetics;2024-07-24

2. Neoadjuvant chemoradiotherapy for thoracic esophageal squamous cell carcinoma: does everyone need it?;Siberian journal of oncology;2024-05-10

3. Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: A systematic review and meta‐analysis;Cancer Medicine;2024-02

4. Efficacy and Safety of Pembrolizumab Combined with Albumin-Bound Paclitaxel and Nedaplatin for Advanced Esophageal Squamous Cell Carcinoma;Immunotherapy;2024-01-10

5. High-dose chemotherapy sensitizes locally advanced esophageal squamous cell carcinoma to PD-1 blockade for a higher pathological complete response rate and survival;Translational Oncology;2023-10